HN2012000708A - Anticuerpos monoclonales frente a progastrina y sus uso - Google Patents

Anticuerpos monoclonales frente a progastrina y sus uso

Info

Publication number
HN2012000708A
HN2012000708A HN2012000708A HN2012000708A HN2012000708A HN 2012000708 A HN2012000708 A HN 2012000708A HN 2012000708 A HN2012000708 A HN 2012000708A HN 2012000708 A HN2012000708 A HN 2012000708A HN 2012000708 A HN2012000708 A HN 2012000708A
Authority
HN
Honduras
Prior art keywords
progastrine
antibodies
methods
monotional
compositions
Prior art date
Application number
HN2012000708A
Other languages
English (en)
Inventor
Julie Pannequin
Laure Bodier
Dominique Jobert
Frederic Hollande
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012000708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of HN2012000708A publication Critical patent/HN2012000708A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Abstract

LA PRESENTE DESCRIPCION ESTA DIRIGIDA A ANTICUERPOS MONOCIONALES DE PROGASTRINA, A FRAGMENTOS DE ESTOS, A COMPOSICIONES QUE COMPRENDEN ANTICUERPOS MONOCIONALES DE PROGRASTRINA Y METODOS PARA PREPARAR Y USAR LOS ANTICUERPOS MONOCIONALES DE PROGRASTRINA Y COMPOSICIONES DE ESTOS. LA PRESENTE DESCRIPCION ESTA DIRIGIDA A METODOS PARA TRATAR CANCER COLORRECTAL CON ANTICUERPOS MONOCIONALES DE PROGASTRINA Y A COMPOSICIONES QUE COMPRENDEN ANTICUERPOS MONOCLONALES DE PROGASTRINA O FRAGMENTOS DE ESTOS. LA PRESENTE DESCRIPCION ESTA DIRIGIDA ADEMAS A METODOS QUE COMPRENDEN LA DETECCION DE PROGASTRINA, INCLUYENDO METODOS PARA DIAGNOSTICAR CANCER COLORRECTAL Y METODOS PARA MONITORIZAR LA EFICACIA DE TERAPIA ANTI-CANCEROSA EN SUJETOS QUE PADECEN CANCER COLORRECTAL.
HN2012000708A 2009-10-16 2012-04-13 Anticuerpos monoclonales frente a progastrina y sus uso HN2012000708A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
HN2012000708A true HN2012000708A (es) 2015-06-22

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012000708A HN2012000708A (es) 2009-10-16 2012-04-13 Anticuerpos monoclonales frente a progastrina y sus uso

Country Status (40)

Country Link
US (7) US9611320B2 (es)
EP (2) EP3421493B1 (es)
JP (3) JP5985987B2 (es)
KR (2) KR20120091221A (es)
CN (2) CN104628857A (es)
AP (1) AP2012006262A0 (es)
AR (1) AR078659A1 (es)
AU (1) AU2010306119A1 (es)
CA (1) CA2777691C (es)
CL (1) CL2012000914A1 (es)
CR (1) CR20120184A (es)
CU (1) CU24196B1 (es)
CY (1) CY1120913T1 (es)
DK (1) DK2488551T3 (es)
EA (2) EA201791876A1 (es)
EC (1) ECSP12011796A (es)
ES (1) ES2690943T3 (es)
GE (1) GEP201706604B (es)
GT (1) GT201200114A (es)
HK (1) HK1178183A1 (es)
HN (1) HN2012000708A (es)
HR (1) HRP20181645T1 (es)
IL (2) IL219019B (es)
IN (1) IN2012DN03348A (es)
LT (1) LT2488551T (es)
MA (1) MA33747B1 (es)
MX (1) MX351635B (es)
NI (1) NI201200054A (es)
NZ (2) NZ599971A (es)
PE (1) PE20121649A1 (es)
PL (1) PL2488551T3 (es)
PT (1) PT2488551T (es)
RS (1) RS57966B1 (es)
SG (1) SG10201704933PA (es)
SI (1) SI2488551T1 (es)
TN (1) TN2012000159A1 (es)
TW (1) TWI537002B (es)
UA (1) UA106771C2 (es)
WO (1) WO2011045080A2 (es)
ZA (1) ZA201202642B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
AR078659A1 (es) * 2009-10-16 2011-11-23 Biorealites S A Anticuerpos monoclonales contra progastrina humana y sus usos
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
BR112012024036B1 (pt) * 2010-03-24 2020-03-03 Les Laboratoires Servier Profilaxia de câncer colorretal e gastrointestinal
US10533050B2 (en) * 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
US8785603B2 (en) * 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US9410955B2 (en) 2011-06-01 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the risk of developing a colonic neoplasia
EP3708189B1 (en) 2013-07-05 2023-11-29 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
MX2016013686A (es) * 2014-04-18 2017-03-31 Univ New York State Res Found Anticuerpos de antigeno anti-tf humanizado.
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
EP3349768A4 (en) * 2015-09-15 2019-01-23 The Scripps Research Institute ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF
ES2901602T3 (es) * 2015-12-31 2022-03-23 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer ovárico
BR112018013268A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer gástrico
BR112018013269A2 (pt) * 2015-12-31 2018-12-11 Syncerus S A R L composições e métodos para a avaliação do risco de ocorrência do câncer
EA201992315A1 (ru) * 2017-03-30 2020-03-04 Прогастрин Э Кансер С.А Р.Л. Композиции и способы для лечения рака легкого
KR102351556B1 (ko) * 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
ES2920283T3 (es) * 2017-12-05 2022-08-02 Progastrine Et Cancers S A R L Terapia de combinación entre un anticuerpo antiprogastrina y la inmunoterapia para tratar el cáncer
JP7338128B2 (ja) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル 癌診断における放射性標識プロガストリン
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
US20200400675A1 (en) * 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN117567611A (zh) * 2023-11-22 2024-02-20 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
WO2007135542A2 (en) * 2006-05-22 2007-11-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Progastrin inhibitors in the treatment of colon cancer
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AR078659A1 (es) * 2009-10-16 2011-11-23 Biorealites S A Anticuerpos monoclonales contra progastrina humana y sus usos

Also Published As

Publication number Publication date
MX2012004400A (es) 2012-06-27
PE20121649A1 (es) 2012-12-08
KR101640520B1 (ko) 2016-07-19
HK1178183A1 (zh) 2013-09-06
EP3421493C0 (en) 2024-01-17
PT2488551T (pt) 2018-10-31
CY1120913T1 (el) 2019-12-11
MA33747B1 (fr) 2012-11-01
US11299542B2 (en) 2022-04-12
CA2777691C (en) 2018-02-27
US10385126B2 (en) 2019-08-20
EA029271B1 (ru) 2018-03-30
AR078659A1 (es) 2011-11-23
MX351635B (es) 2017-10-23
JP2015145380A (ja) 2015-08-13
EP2488551B1 (en) 2018-07-25
TN2012000159A1 (en) 2013-12-12
CR20120184A (es) 2012-08-20
US10385124B2 (en) 2019-08-20
US10377821B2 (en) 2019-08-13
RS57966B1 (sr) 2019-01-31
ECSP12011796A (es) 2012-06-29
US20180022802A1 (en) 2018-01-25
GEP201706604B (en) 2017-01-25
EA201200597A1 (ru) 2012-12-28
GT201200114A (es) 2014-08-11
WO2011045080A3 (en) 2011-07-07
US20170306012A1 (en) 2017-10-26
KR20120091221A (ko) 2012-08-17
LT2488551T (lt) 2018-10-25
US20200002413A1 (en) 2020-01-02
US20220195035A1 (en) 2022-06-23
KR20150082672A (ko) 2015-07-15
US9611320B2 (en) 2017-04-04
NZ701709A (en) 2016-06-24
EA201791876A1 (ru) 2018-01-31
IL219019B (en) 2019-05-30
TWI537002B (zh) 2016-06-11
WO2011045080A2 (en) 2011-04-21
IL254004B2 (en) 2023-06-01
HRP20181645T1 (hr) 2018-12-14
CU24196B1 (es) 2016-09-30
IN2012DN03348A (es) 2015-10-23
PL2488551T3 (pl) 2019-01-31
AU2010306119A1 (en) 2012-05-03
CN102791735A (zh) 2012-11-21
UA106771C2 (uk) 2014-10-10
TW201119675A (en) 2011-06-16
US20110117086A1 (en) 2011-05-19
CL2012000914A1 (es) 2012-09-14
JP2013507138A (ja) 2013-03-04
EP3421493A1 (en) 2019-01-02
SG10201704933PA (en) 2017-07-28
AP2012006262A0 (en) 2012-06-30
DK2488551T3 (en) 2018-10-08
JP6272793B2 (ja) 2018-01-31
CU20120060A7 (es) 2013-04-19
US20170306011A1 (en) 2017-10-26
BR112012008818A2 (pt) 2018-05-22
ZA201202642B (en) 2013-06-26
CA2777691A1 (en) 2011-04-21
EP3421493B1 (en) 2024-01-17
IL219019A0 (en) 2012-06-28
CN104628857A (zh) 2015-05-20
IL254004A0 (en) 2017-10-31
US20170174761A1 (en) 2017-06-22
ES2690943T3 (es) 2018-11-23
US10385125B2 (en) 2019-08-20
EP2488551A2 (en) 2012-08-22
JP2017212992A (ja) 2017-12-07
JP5985987B2 (ja) 2016-09-06
NZ599971A (en) 2014-12-24
NI201200054A (es) 2012-08-20
SI2488551T1 (sl) 2019-01-31
CN102791735B (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
HN2012000708A (es) Anticuerpos monoclonales frente a progastrina y sus uso
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
CO6680609A2 (es) Composición acuosa que contiene bromhexina
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
SV2011003891A (es) Antagonistas de los receptores tipo toll 3
CR20140497A (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
ECSP11011376A (es) Dispositivo y procedimiento para la verificación y para el análisis cuantitativo de analitos, particularmente de micotoxinas
CL2008000818A1 (es) Uso de polipeptido de il-18 humana y un anticuerpo anti-cd para tratar o prevenir cancer.
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
CL2009001155A1 (es) Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
ES2572368T3 (es) Tratamiento de la artrosis
CL2012003201A1 (es) Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.
BR112014000670A2 (pt) uso de compostos oligossacarídeo para a prevenção e tratamento de cicatrizes patológicas